Diana Radu Djurfeldt

Diana Radu Djurfeldt

Auto-generated profile, based on publicly available information

Diana Radu Djurfeldt

Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, and Stockholm Health Care Services, Region Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2020 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
HWHemmings Wu
Hemmings Wu
MHMarwan Hariz
Marwan Hariz
VVVeerle Visser-Vandewalle
Veerle Visser-Vandewalle
LZLudvic Zrinzo
Ludvic Zrinzo
VCVolker A. Coenen
Volker A. Coenen
BNBart Nuttin
Bart Nuttin
A consensus has yet to emerge whether deep brain stimulation (DBS) for treatment-refractory obsessive-compulsive disorder (OCD) can be considered an established therapy. In 2014, the World Society for Stereotactic and Functional Neurosurgery (WSSFN) published consensus guidelines stating that a therapy becomes established when “at least two blinded randomized controlled clinical trials from two different groups of researchers are published, both reporting an acceptable risk-benefit ratio, at least comparable with other existing therapies. The clinical trials should be on the same brain area for the same psychiatric indication.” The authors have now compiled the available evidence to make a clear statement on whether DBS for OCD is established therapy. Two blinded randomized controlled trials have been published, one with level I evidence (Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score improved 37% during stimulation on), the other with level II evidence (25% improvement). A clinical cohort study (N = 70) showed 40% Y-BOCS score improvement during DBS, and a prospective international multi-center study 42% improvement (N = 30). The WSSFN states that electrical stimulation for otherwise treatment refractory OCD using a multipolar electrode implanted in the ventral anterior capsule region (including bed nucleus of stria terminalis and nucleus accumbens) remains investigational. It represents an emerging, but not yet established therapy. A multidisciplinary team involving psychiatrists and neurosurgeons is a prerequisite for such therapy, and the future of surgical treatment of psychiatric patients remains in the realm of the psychiatrist.

1 July 2015 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
EAErik Andersson
Erik Andersson
EHErik Hedman
Erik Hedman
JEJesper Enander
Jesper Enander
DDDiana Radu Djurfeldt
Diana Radu Djurfeldt
BLBrjánn Ljótsson
Brjánn Ljótsson
CRChristian Rück
Christian Rück
Although cognitive behavioral therapy (CBT) is an effective treatment for obsessive-compulsive disorder (OCD), with responder rates averaging 62% to 72%1,2 a significant proportion of patients do not achieve satisfactory symptom relief. One possible way to further improve treatment efficacy is to enhance CBT with pharmacotherapy. Serotonin reuptake inhibitors are effective for OCD in their own right, but no synergistic effects of the 2 treatment modalities have been convincingly demonstrated compared with CBT alone.3 One compound that has shown promise as an adjunct to CBT for OCD is d-cycloserine (DCS).4 It affects the glutamate system by acting as a partial agonist at the N-methyl-d-aspartate (NMDA) receptor, which is crucially implicated in fear learning and fear extinction in both rats and humans.4 Specifically, NMDA antagonists block fear extinction in rats, whereas NMDA agonists enhance fear extinction.5 In CBT for OCD, patients gradually face anxiety-provoking cues and simultaneously refrain from carrying out rituals, an approach known as exposure with response prevention (ERP).6 As ERP is based on the principles of fear extinction, DCS may be a viable augmentation strategy for these patients. To date, 3 of 5 randomized clinical trials of DCS-augmented CBT for OCD have found that DCS augmentation may lead to a faster treatment response than placebo, but results are inconsistent as to whether DCS is superior to placebo at posttreatment or follow-up.7-11 However, these previous trials had modest sample sizes (N = 24-30) and may therefore have been underpowered to detect subtle differences between DCS and placebo. Additional variables such as number of CBT sessions, the dose and number of DCS capsules, the timing of drug administration, and the success of the exposure sessions may also contribute to the conflicting results obtained to date.12-14

22 May 2012 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
SCS Cervenka
S Cervenka
EHE Hedman
E Hedman
YIY Ikoma
Y Ikoma
DDD Radu Djurfeldt
D Radu Djurfeldt
CRC Rück
C Rück
NLN Lindefors
N Lindefors
The dopamine system has been suggested to play a role in social anxiety disorder (SAD), partly based on molecular imaging studies showing reduced levels of striatal dopaminergic markers in patients compared with control subjects. However, the dopamine system has not been examined in frontal and limbic brain regions proposed to be central in the pathophysiology of SAD. In the present study, we hypothesized that extrastriatal dopamine D2-receptor (D2-R) levels measured using positron emission tomography (PET) would predict symptom reduction after cognitive behavior therapy (CBT). Nine SAD patients were examined using high-resolution PET and the high-affinity D2-R antagonist radioligand [11C]FLB 457, before and after 15 weeks of CBT. Symptom levels were assessed using the anxiety subscale of Liebowitz Social Anxiety Scale (LSASanx). At posttreatment, there was a statistically significant reduction of social anxiety symptoms (P<0.005). Using a repeated measures analysis of covariance, significant effects for time and time × LSASanx change on D2-R-binding potential (BPND) were shown (P<0.05). In a subsequent region-by-region analysis, negative correlations between change in D2-R BPND and LSASanx change were found for medial prefrontal cortex and hippocampus (P<0.05). This is the first study to report a direct relationship between symptom change after psychological treatment and a marker of brain neurotransmission. Using an intra-individual comparison design, the study supports a role for the dopamine system in cortical and limbic brain regions in the pathophysiology of SAD.

1 July 2015 in Behavior Therapy
Verified
Journal Article
Closed access
JLJohanna Linde
Johanna Linde
CRChristian Rück
Christian Rück
JBJohan Bjureberg
Johan Bjureberg
VIVolen Z. Ivanov
Volen Z. Ivanov
DDDiana Radu Djurfeldt
Diana Radu Djurfeldt
JRJonas Ramnerö
Jonas Ramnerö

25 August 2021 in medRxiv
Verified
Preprint
Open access
PDF file
OFOskar Flygare
Oskar Flygare
EAErik Andersson
Erik Andersson
GGGjermund Glimsdal
Gjermund Glimsdal
DMDavid Mataix-Cols
David Mataix-Cols
DDDiana Djurfeldt
Diana Djurfeldt
JEJesper Enander
Jesper Enander
Objectives To evaluate the cost-effectiveness of internet-delivered cognitive behaviour therapy for body dysmorphic disorder (BDD-NET). Design Secondary cost-effectiveness analysis from a randomised controlled trial on BDD-NET versus online supportive psychotherapy. Setting Academic medical centre. Participants Self-referred adult patients with a primary diagnosis of body dysmorphic disorder and a score of 20 or higher on the modified Yale-Brown obsessive compulsive scale (n = 94). Patients receiving concurrent psychotropic drug treatment were included if the dose had been stable for at least two months and remained unchanged during the trial. Interventions Participants received either BDD-NET (n = 47) or online supportive psychotherapy (n = 47) for 12 weeks. Primary and secondary outcome measures The primary outcome measures were cost-effectiveness and cost-utility from a societal perspective, using remission status from a diagnostic interview and quality-adjusted life years from EQ-5D, respectively. Secondary outcome measures were cost-effectiveness and cost-utility from a health care perspective and the clinic’s perspective. Results Compared to supportive psychotherapy, BDD-NET produced one additional remission for an average societal cost of $4132. The cost-utility analysis showed that BDD-NET generated one additional QALY to an average cost of $14319 from a societal perspective. Conclusions BDD-NET is a cost-effective treatment for body dysmorphic disorder, compared to online supportive psychotherapy. The efficacy and cost-effectiveness of BDD-NET should be directly compared to face-to-face cognitive behaviour therapy. Trial registration NCT02010619 Strengths and limitations of this study This is the first cost-effectiveness evaluation of a novel internet-delivered treatment designed to increase access to cognitive behaviour therapy for patients with body dysmorphic disorder Cost estimations were self-rated and might not capture all costs associated with treatment The self-referred participants were likely motivated to undergo treatment.